For All The Latest Medical News, Health News, Research News, COVID-19 News, Dengue News, Glaucoma News, Diabetes News, Herb News, Phytochemical News, Cardiology News, Epigenetic News, Cancer News, Doctor News, Hospital News
COVID-19 News: U.S. FDA Halts Usage Of Bebtelovimab To Treat COVID-19 As Drug Is Not Able To Neutralize New SARS-CoV-2 Variants And Sub-Lineages!
COVID-19 News - Bebtelovimab Dec 01, 2022 2 years, 3 weeks, 16 hours, 29 minutes ago
COVID-19 News: The U.S. FDA issued an announcement in the last 24 hours stating that Bebtelovimab is not currently authorized in any U.S. region to treat COVID-19.
However, with the emergence of more than 300 odd new Omicron variants and sub-linages and also recombinant variants that are more transmissible and immune evasive and able to cause breakthrough infections that has already been covered in various COVID-19 News coverages, even Bebtelovimab the last standing monoclonal therapeutic after Evusheld, has been found to be ineffective.
In actual reality, the world is really is a worse state compared to initial onset of the COVID-19 pandemic as it does not really have any more drugs left in its arsenal to fight SARS-CoV-2 infections and considering the current kinetics of the pandemic where millions are infected with varying variants in different geolocations and there are simply no more preventive measures nor travel restrictions with a huge variety of variants and sub-lineages in circulation. Although we are not yet seeing a rise in disease severity nor deaths, it is only a matter of time before new mutations that drive enhanced pathogenesis and virulence appear.
While the U.S, FDA still insist that the antivirals Paxlovid, Remdesivir (Veklury) and Molnupiravir (Lagevrio) are still effective to treat COVID-19, many researchers and physicians have already written them off due to a variety of reasons.
Remdesivir has been found to be ineffective in treating COVID-19 along with the fact that it causes a variety of adverse issues and is toxic.
Hence, there is no antiviral left to deal with the emerging SARS-CoV-2 variants and sub-lineages.
Some of the fraudulent doctors and groups that are promoting ivermectin to treat COVID-19 are not even aware that since the advent of the delta variant, ivermectin has no whatsoever efficacy against the Omicron variant or even the newer emerging sub-lineages and is no better than a placebo although newer emerging data shows that extended use can cause dysbiosis which can affect the immune system and make people even more susceptible to not only the virus but other secondary opportunistic pathogens.